<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725254</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-008</org_study_id>
    <nct_id>NCT03725254</nct_id>
  </id_info>
  <brief_title>CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC</brief_title>
  <official_title>Curative Chemoradiotherapy Versus Radical Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the effects of chemoradiation versus radical surgery in treating
      retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer. By prolonging
      patients' progression-free survival, local control rate and overall survival, investigators
      can conclude the best regimen for colorectal cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomization until the date of disease progressed for any reason, assessed up to 5 years</time_frame>
    <description>The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works. Also called PFS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works. Also called OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>From date of randomization until the date of disease recurrece, assessed up to 5 years</time_frame>
    <description>no recurrence of the retroperitoneal or paraaortic lymph node region.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Retroperitoneal Lymph Node Metastasis</condition>
  <condition>Para-aortic Lymph Node Metastasis</condition>
  <arm_group>
    <arm_group_label>radical surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radical chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy</intervention_name>
    <description>The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.</description>
    <arm_group_label>radical surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiotherapy</intervention_name>
    <description>Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).</description>
    <arm_group_label>radical chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A medical history of colorectal cancer

          -  Pathological or clinical diagnosis of retroperitoneal/para-vascular lymph node
             metastases, and located below the level of renal veins.

          -  The treatment target is no evidence of disease (NED), including 3 cohorts:

        A. Initial treatment (primary lesion + retroperitoneal LN oligometastasis); B.
        Postoperative retroperitoneal/paravascular LN oligometastase; C. Postoperative
        retroperitoneal/paravascular LN metastasis with other organ metastases (up to NED)

          -  ECOG PS 0-2

          -  Ability to follow the program during the study period

          -  Signing written informed consent

        Exclusion Criteria:

          -  Retroperitoneal LN metastasis is above the level of the renal vein.

          -  Unable to reach NED.

          -  Previous pelvic radiotherapy, the field of irradiation overlaps with this time.

          -  Pregnancy or breastfeeding women.

          -  Those with other history of malignant disease in the last 5 years, except for cured
             skin cancer and cervical carcinoma in situ.

          -  If there is an uncontrolled history of epilepsy, central nervous system disease or
             mental disorder, the investigator may determine that the clinical severity may hinder
             the signing of informed consent or affect the patient's oral medication compliance.

          -  Clinically severe (ie, active) heart disease, such as symptomatic coronary heart
             disease, New York Heart Association (NYHA) class II or more severe congestive heart
             failure or severe arrhythmia requiring medication intervention, Or a history of
             myocardial infarction in the last 12 months

          -  Organ transplantation requires immunosuppressive therapy

          -  Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant
             diseases

          -  Subjects Blood routine and biochemical indicators do not meet the following criteria:
             hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelets ≥ 100
             × 109 / L; ALT, AST≤2.5 times normal upper limit; ALP≤2.5 times normal upper limit;
             serum total bilirubin &lt;1.5 times normal upper limit; serum creatinine &lt;1 times normal
             upper limit; serum albumin ≥30g/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>+86-2164175590</phone>
    <phone_ext>81607</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Zhu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>January 19, 2019</last_update_submitted>
  <last_update_submitted_qc>January 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhu Ji</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>retroperitoneal lymphadenectomy</keyword>
  <keyword>IMRT</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

